Bristol myers squibb receives approval from the european commission to expand use of car t cell therapy breyanzi for relapsed or refractory follicular lymphoma

Princeton, n.j.--(business wire)---- $bmy #breyanzi--bms receives approval from the european commission to expand use of car t cell therapy breyanzi for relapsed or refractory follicular lymphoma.

CAR Ratings Summary

CAR Quant Ranking